Aligos Therapeutics Inc. has identified prodrugs reported to be useful for the treatment of hepatitis B and hepatitis D viral infections.

Xuanzhu Pharma Co. Ltd. has synthesized kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.

Researchers at CNCCS Scarl (Collezione Nazionale Dei Composti Chimici E Centro Screening) and IRBM SpA have disclosed tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP2) inhibitors reported to be useful for the treatment of cancer, Noonan and Leopard syndrome.

New York University has described protein spinster homolog 2 (SPNS2) inhibitors reported to be useful for the treatment of acute lung injury, autoimmune disease, colitis, Alzheimer’s disease, fibrosis, inflammatory bowel disease, multiple sclerosis and rheumatoid arthritis.

Teon Therapeutics Inc. has divulged 5’-nucleotidase (CD73) inhibitors reported to be useful for the treatment of cancer.

Nankai University has identified harringtonine derivatives reported to be useful for the treatment of cancer.

Shenzhen Zhongge Biotechnology Co. Ltd. has synthesized tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or PTPN2 (TCPTP) inhibitors reported to be useful for the treatment of cancer, obesity, atherosclerosis, type 1 diabetes, type 2 diabetes, neurodegeneration, metabolic syndrome and inflammatory bowel disease, among others.

Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has disclosed compounds reported to be useful for the treatment of arterial aneurysm.

Pfizer Inc. has described serine/threonine-protein kinase (SIK) inhibitors reported to be useful for the treatment of arthritis, cancer, osteoporosis, atherosclerosis, inflammatory bowel disease, autoimmune diseases, inflammatory disorders and pain.

Shanghai Apeiron Biotechnology Co. Ltd. has divulged protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.